Tumour mutational burden (TMB) quantifies the number of mutations per megabase (Mb) in the tumour genome, and those with a high TMB (TMB-H) tend to have more immunogenic neoantigens and greater sensitivity to anti-PD-(L)1 therapy. The gene discussed is CD274; the disease is neoplasm.